[{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"6597b7e7-80e5-4a8e-9881-9c013dcb4c2e","acronym":"AHEAD-MERIT","url":"https://clinicaltrials.gov/study/NCT04534205","created_at":"2021-01-18T21:42:20.218Z","updated_at":"2025-02-25T16:26:00.326Z","phase":"Phase 2","brief_title":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","source_id_and_acronym":"NCT04534205 - AHEAD-MERIT","lead_sponsor":"BioNTech SE","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • BNT113"],"overall_status":"Recruiting","enrollment":" Enrollment 285","initiation":"Initiation: 01/07/2021","start_date":" 01/07/2021","primary_txt":" Primary completion: 05/01/2028","primary_completion_date":" 05/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-01-28"},{"id":"b40fb89a-d042-4bf3-862c-f905fdac4d70","acronym":"VERSATILE-002","url":"https://clinicaltrials.gov/study/NCT04260126","created_at":"2021-01-18T20:42:10.407Z","updated_at":"2025-02-25T16:09:57.311Z","phase":"Phase 2","brief_title":"Study of PDS0101 and Pembrolizumab Combination I/O in Subjects with HPV16 + Recurrent And/or Metastatic HNSCC","source_id_and_acronym":"NCT04260126 - VERSATILE-002","lead_sponsor":"PDS Biotechnology Corp.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Versamune HPV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 03/29/2021","start_date":" 03/29/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-12-18"},{"id":"3ebe9afc-734e-40aa-b8ff-0cbea23c45dc","acronym":"IMMUNOCERV","url":"https://clinicaltrials.gov/study/NCT04580771","created_at":"2021-01-18T21:51:39.762Z","updated_at":"2024-07-02T16:34:59.039Z","phase":"Phase 2","brief_title":"A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial","source_id_and_acronym":"NCT04580771 - IMMUNOCERV","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Versamune HPV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 10/14/2020","start_date":" 10/14/2020","primary_txt":" Primary completion: 03/08/2025","primary_completion_date":" 03/08/2025","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2024-06-04"},{"id":"6f412c81-9eb0-48e7-8b40-e0e8b91d12d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05582590","created_at":"2022-10-17T13:56:01.481Z","updated_at":"2024-07-02T16:35:23.356Z","phase":"Phase 1","brief_title":"Autologous T Cells Targeting HPV16 HPV18 \u0026 Survivin in Patients With R/R HPV-related Oropharyngeal Cancers","source_id_and_acronym":"NCT05582590","lead_sponsor":"NexImmune Inc.","biomarkers":" HLA-A","pipe":"","alterations":" ","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NEXI-003"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 08/25/2027","study_completion_date":" 08/25/2027","last_update_posted":"2024-01-15"},{"id":"c04546a7-eee3-4054-89be-d7ee08a9cd8a","acronym":"OpcemISA","url":"https://clinicaltrials.gov/study/NCT03669718","created_at":"2021-01-18T18:00:19.264Z","updated_at":"2024-07-02T16:35:24.902Z","phase":"Phase 2","brief_title":"A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC","source_id_and_acronym":"NCT03669718 - OpcemISA","lead_sponsor":"ISA Pharmaceuticals","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • ISA101b"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 194","initiation":"Initiation: 11/30/2018","start_date":" 11/30/2018","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-12-29"},{"id":"b54c377f-73ac-4c27-8f1c-a96d3052690a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499795","created_at":"2023-07-03T22:09:19.913Z","updated_at":"2024-07-02T16:35:42.988Z","phase":"Phase 2","brief_title":"VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2","source_id_and_acronym":"NCT03499795","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" CD8 • TNFRSF9","pipe":" | ","alterations":" CD8 positive","tags":["CD8 • TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bizalimogene ralaplasmid (VGX-3100)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 05/15/2018","start_date":" 05/15/2018","primary_txt":" Primary completion: 06/16/2020","primary_completion_date":" 06/16/2020","study_txt":" Completion: 05/26/2021","study_completion_date":" 05/26/2021","last_update_posted":"2023-07-14"},{"id":"ca15d8ce-e16c-480b-8a2f-ce77b4af05ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05122221","created_at":"2021-11-16T12:53:40.624Z","updated_at":"2024-07-02T16:36:08.200Z","phase":"Phase 1","brief_title":"CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers","source_id_and_acronym":"NCT05122221","lead_sponsor":"Corregene Biotechnology Co., Ltd","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CRTE7A2-01 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/17/2022","start_date":" 07/17/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-06-28"},{"id":"97e099ff-5286-4e2a-86a3-91ea5e73a0b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03439085","created_at":"2021-01-29T07:16:58.643Z","updated_at":"2024-07-02T16:36:17.195Z","phase":"Phase 2","brief_title":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers","source_id_and_acronym":"NCT03439085","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • rocakinogene sifuplasmid (INO-9012) • INO-3112"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 11/14/2018","start_date":" 11/14/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-02-14"},{"id":"fa08c05c-fc62-4ad7-b7eb-1a091aa3c5dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02172911","created_at":"2021-02-21T23:52:45.454Z","updated_at":"2024-07-02T16:36:34.313Z","phase":"Phase 1/2","brief_title":"A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer","source_id_and_acronym":"NCT02172911","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-3112"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 06/06/2014","start_date":" 06/06/2014","primary_txt":" Primary completion: 09/07/2017","primary_completion_date":" 09/07/2017","study_txt":" Completion: 09/07/2017","study_completion_date":" 09/07/2017","last_update_posted":"2021-02-21"},{"id":"9191d14a-5359-4697-90d1-ac86b9cf4e22","acronym":"","url":"https://clinicaltrials.gov/study/NCT02163057","created_at":"2021-01-18T10:04:15.979Z","updated_at":"2024-07-02T16:36:35.792Z","phase":"Phase 1/2","brief_title":"Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT02163057","lead_sponsor":"Inovio Pharmaceuticals","biomarkers":" CD8 • CD69 • TNFRSF9 • GZMB • FOXP3 • GZMA • PRF1","pipe":" | ","alterations":" TILs","tags":["CD8 • CD69 • TNFRSF9 • GZMB • FOXP3 • GZMA • PRF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e INO-3112"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 08/13/2014","start_date":" 08/13/2014","primary_txt":" Primary completion: 01/23/2017","primary_completion_date":" 01/23/2017","study_txt":" Completion: 01/23/2017","study_completion_date":" 01/23/2017","last_update_posted":"2021-01-22"}]